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ABSTRACT
To investigate the clinicopathologic characteristics and the prognostic impact of 
PIK3CA gene amplification in curatively resected esophageal squamous cell carcinoma 
(ESCC). Using 534 curatively resected ESCCs, the PIK3CA gene copy number was 
evaluated with fluorescent in situ hybridization. PIK3CA amplification was defined 
as PIK3CA/centromere 3 ratio is ≥ 2.0 or average number of PIK3CA signals/
tumor cell nucleus ≥ 5.0. PIK3CA mutations in exon 9 and 20, encoding the highly 
conserved helical and kinase domains were assessed by direct sequencing in 388 
cases. PIK3CA amplification was detected in 56 (10.5%) cases. PIK3CA amplification 
was significantly associated with higher T-stage (P=0.026) and pathologic stage 
(P=0.053). PIK3CA amplification showed a significantly shorter disease free survival 
(DFS) compared with that of non-amplified group (33.4 vs 63.1 months, P=0.019). 
After adjusting for gender, tumor location, pathologic stage, histologic grade and 
adjuvant treatment, PIK3CA amplification was significantly associated with a shorter 
DFS (adjusted hazard ratio [AHR] 1.53; 95% CI, 1.10-2.17; P=0.02). Though the 
statistical insignificance, PIK3CA amplification showed tendency of shorter OS (52.1 
vs 96.5 moths, P=0.116). PIK3CA mutations were detected in 6 (1.5%) of 388 cases; 
5 cases with exon 9 mutations in E545K while one exon 20 mutation in H1047L. 
PIK3CA amplification is a frequent oncogenic alteration and associated with shorter 
survival, suggesting its role as a prognostic biomarker in resected ESCC. PIK3CA 
amplification may represent a promising therapeutic target for ESCC.
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INTRODUCTION
Esophageal cancer (EC) is the sixth most common 
cause of cancer death and the eighth most common cancer 
worldwide [1]. Despite the improvement in diagnosis 
and multidisciplinary treatment, the prognosis remains 
poor, even for patients who undergo complete resection 
[2]. Overall, though the conventional chemotherapy 
incorporating 5-fluorouracil, cisplatin, irinotecan and 
taxane, median overall survival remains 10-12 months 
with frequent toxicities [3]. The limited improvement 
with conventional therapies prompts us to explore 
the molecular biology and identify of prognostic and 
druggable biomarkers.
There are two main histologic types of esophageal 
cancer, esophageal adenocarcinoma (EAC) and esophageal 
squamous cell carcinoma (ESCC). EAC is associated with 
gastroesophageal reflux disease, Barrett’s esophagus, and 
obesity [4-6], predominant in the United States and most 
other Western countries. However, ESCC dominates with 
80% of all cases worldwide and predominant in Asia. In 
contrast to EAC, smoking and alcohol abuse contribute 
to the development of ESCC [7]. With those distinct 
biologic and epidemiologic differences, EAC and ESCC 
may need different therapeutic approaches. Over the past 
decade, molecular targeted therapy blocking important 
oncogenic pathway including human epidermal growth 
factor receptor-2 (HER2; also known as ERBB2) have 
led to remarkable progress in EAC including human 
epidermal growth factor receptor-2 (HER2; also known 
as ERBB2) [8]. Despite the improved outcome of EAC, 
ESCC still lacks therapeutically relevant predictive or 
prognostic target. A comparative genomic study revealed 
different genetic alterations between EAC and ESCC [9, 
10]. Copy number gains of SOX2, PIK3CA, CCND1, 
and FGFR1 were more frequent in ESCC than in EAC, 
implicating these genes as therapeutic targets for ESCC. 
Very recently, we reported that FGFR1 amplification is 
frequently observed and an independent prognostic factor 
in resected ESCC [11]. Taken together, PIK3CA may also 
represent an attractive molecular target for ESCC.
Phosphoinisitide 3-kinase (PI3K)/Akt signaling 
pathway regulates cell proliferation, growth, survival, 
apoptosis, and glucose metabolism [12]. Activation of the 
PI3K pathway occurs upon engagement with mutation 
or amplification of PIK3CA, the p110α catalytic subunit 
of PI3K. Amplification and mutation of PIK3CA is 
generally associated with increased PIK3CA expression, 
PI3K activation, and phosphorylation of downstream Akt, 
supporting the oncogenic role of PI3K aberration. PIK3CA 
gene amplification was found in 10-30% of non-small cell 
lung cancer, breast cancer, colon cancer and head/neck 
cancer [13-16]. Activating somatic mutations (codons 
542 and 545 in exon 9 and codon 1047 in exon 20) were 
also identified in various solid tumors [17]. Despite 
accumulating evidence of biologic role, only a few studies 
have reported the frequency of PIK3CA aberration in 
ESCC and its prognostic role is still controversial [18-22].
In this study, we evaluated the frequency of PIK3CA 
amplification and mutation in surgically resected ESCC. 
Furthermore, we also determined the prognostic impact of 
genetic aberration of PIK3CA in ESCC.
RESULTS
Patient characteristics
A total of 534 patients with curative esophagectomy 
were analyzed and their clinicopathologic features are 
presented in Table 1. The majority of patients were male 
(93.4%) with a median age of 65 years (range 31-90). 
Median tumor size was 4 cm and approximately half 
of the tumors were stage pT3 or pN0. Approximately 
two-thirds of cases (54.9%) were located in the lower 
esophagus and one-third in the middle esophagus. 
All patients received radical surgery, with evidence 
of pathologic stage I in 19.9%, stage II in 44.8%, and 
stage III in 35.4%. Two-thirds (63.9%) were moderately 
differentiated carcinoma, and more than half of patients 
located in the lower esophagus. The majority of patients 
were current (39.3%) or former (36.7%) smokers, and the 
median smoking dosage was 25 pack-years (range 0-150). 
Adjuvant treatment was given to 138 patients (25.8%), 
and 62 of these (44.9%) were treated with concurrent 
chemoradiotherapy. Adjuvant therapy was introduced in 
4.7% for stage I, 21.3% for stage II, and 42.9% for stage 
III patients.
Association of PIK3CA amplification status and 
clinicopathologic features
Among 534 patients, 41 (7.7%) of cases satisfied 
both criteria of PIK3CA: CEN3 ratio of ≥ 2.0 and an 
average number of PIK3CA signal per nucleus ≥5.0, 
whereas 15 (2.8%) cases only satisfied the criterion of 
PIK3CA ≥ 5.0 (Supplementary Figure S1). With our 
criteria, PIK3CA amplification was detected in 56 (10.5%) 
cases (Table 1, Figure 1). The median PIK3CA gene 
copy number was 5.4 (range, 4.0-16.0) and 2.1 (range, 
0-3.9) in PIK3CA amplified and non-amplified groups, 
respectively. The mean PIK3CA/CEN3 ratio was 2.3 (0.9-
6.0) for the amplification group and 1.08 (0-1.9) for the no 
amplification group.
There was no significant difference in PIK3CA 
amplification according to age, sex, tumor size, location, 
histologic grade, smoking and adjuvant therapy as 
shown in Table 1. However, PIK3CA amplification was 
significantly associated with a higher T-stage (P=0.026). 
Although only marginal statistical significance was 
achieved, there was a positive association between 
PIK3CA amplification and higher pathologic stage 
(P=0.053). Based on the pattern of amplification 
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Table 1: Patient characteristics according to PIK3CA amplification
Characteristics All patients Amplification* No 
amplification
P†
No. % Ratio Number Total (%) No. %
No of patients 534 100 56 10.5 478 89.5
Age, years 0.183
  Median 65 66 65 66 65 (0.128)
  Range 31-90 51-80 44-72 44-80 31-90
Sex 0.851
  Male 499 93.4 38 14 52 92.9 447 93.5 (0.979)
  Female 35 6.6 3 1 4 7.1 31 6.5
Tumor size, cm 0.148
  Median 4.0 4.0 4.0 4.0 3.0 (0.093)
  Range 0.2-14.5 1-9 1-8 1.0-9.0 0.2-14.5
pT stage‡ 0.026
  T1 153 28.7 7 1 8 14.3 145 30.3 (0.020)
  T2 113 21.2 7 7 14 25.0 99 20.7
  T3 252 47.2 27 7 34 60.7 218 45.6
  T4 16 3.0 0 0 0 0 16 3.3
pN stage‡ 0.426
  N0 261 48.9 16 6 22 39.3 239 50.0 (0.540)
  N1 244 45.7 21 9 30 53.6 214 44.8
  N2 18 3.4 3 0 3 5.4 15 3.1
  N3 11 2.1 1 0 1 1.8 10 2.1
pTMN stage‡ 0.053
  I 106 19.9 7 1 8 14.3 98 20.5 (0.075)
  II 239 44.8 12 8 20 35.7 219 45.8
  III 189 35.4 22 6 28 50.0 161 33.7
Location 0.707
  Cervical 13 2.4 2 0 2 3.6 11 2.3 (0.806)
  Upper 70 13.1 7 2 9 16.1 61 12.8
  Middle 158 29.6 12 6 18 32.1 140 29.3
  Lower 293 54.9 20 7 27 48.2 266 55.6
Histologic grade 0.158
  Well 106 19.9 9 7 16 28.6 90 18.8 (0.080)
  Moderate 341 63.9 28 6 34 60.7 307 64.2
  Poorly 87 16.3 4 2 6 10.7 81 16.9
Smoking status¶ 0.391
  Never-smoker 128 24.0 11 5 16 28.6 112 23.4 (0.634)
  Former smoker 196 36.7 13 3 16 28.6 180 37.7
(Continued)
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(PIK3CA: CEN3 ratio of ≥ 2.0 and signal per nucleus 
≥5.0 vs. PIK3CA signal per nucleus ≥5.0), there 
was similar statistical significance compared to no 
amplification group.
Prognosis according to PIK3CA amplification
The 5 year DFS and OS rates for all patients were 
46.3% and 59.8% with a median follow-up time of 56.4 
Characteristics All patients Amplification* No 
amplification
P†
No. % Ratio Number Total (%) No. %
  Current smoker 210 39.3 17 7 24 42.9 186 38.9
Smoking dosage (pack-years)
  Median 25 30 15 26 25 0.924
  Range 0-150 0-150 0-68 0-150 0-150 (0.645)
Adjuvant therapy 0.077
  Yes 138 25.8 6 3 9 6.5 129 27.0 (0.099)
  No 396 74.2 38 9 47 83.9 349 73.0
PIK3CA FISH§
  Number (median, range) 2.2 (0-16.0) 4.6 (4.0-16.0)
5.6 
(5.0-6.0) 5.4 (4.0-16.0) 2.1 (0-3.9) <0.001
  Ratio (mean, range) 1.1 (0-6.0) 2.5 (2.0-6.0)
1.5 
(0.9-1.9) 2.3 (0.9-6.0) 1.1 (0-1.9) <0.001
Abbreviations: *PIK3CA amplification was defined as if one of the following criteria is fulfilled: (1) Ratio: PIK3CA/CEP3 
ratio is ≥ 2.0, (2) Number: average number of PIK3CA signal per nucleus ≥ 5.0
†χ2 test, Fisher’s exact test, or Mann-Whitney U test. Parenthesis indicates comparisons among ratio, numbers, and non-
amplified groups
‡Pathologic stage at the time of surgical resection was determined according to the American Joint Committee on Cancer 
(seventh edition) guidelines.
¶Never-smokers; a lifetime smoking dose of fewer than 100 cigarettes; former smokers, those who have stopped smoking 
for more than 1 year; current smokers, those who currently smoke or have quit for less than 1 year.
§ PIK3CA numbers are average numbers of PIK3CA signals per nucleus, and ratios are PIK3CA/CEN3 ratios.
Figure 1: Representative fluorescent in situ hybridization of tumors with A. and without B. PIK3CA amplification. FISH 
analysis demonstrated an increase in the signals of PIK3CA (red signals) compared to reference CEN3 (green signals).
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months. The 5-year DFS rate according to pTNM stages 
was 64.6% in stage I, 55.4% in stage II, and 28.9% in 
stage III. The 5-year OS rate according to pTNM stages 
were 76.7% for stage I, 61.3% for stage II, and 32.4% for 
stage III.
PIK3CA amplification showed a significantly 
shorter DFS compared with that of non-amplified group 
(33.4 vs 63.1 months, P=0.019, Figure 2A). Though the 
statistical insignificance probably due to small sample 
size, PIK3CA amplification showed a tendency of shorter 
OS than no amplification (52.1 vs 96.5 months, P=0.116, 
Figure 2B). In the Cox proportional hazard model adjusted 
for gender, tumor location, pathologic stage, histologic 
grade and adjuvant treatment, PIK3CA amplification 
was significantly associated with a shorter DFS (adjusted 
hazard ration [AHR] 1.53; 95% CI, 1.10-2.17; P=0.02, 
Table 2). There was trend toward worse DFS for the 
pattern of amplification (AHR 1.53; 95% CI 1.1-2.3 for 
PIK3CA: CEN3 ratio of ≥ 2.0 vs AHR 1.32; 95% CI, 0.97-
2.56; PIK3CA signal per nucleus ≥5.0; P=0.05) compared 
to non-amplified group. There was no significant 
difference in OS according to PIK3CA amplification, 
gender and adjuvant treatment in multivariate analysis. 
Regarding the prognostic role of PIK3CA amplification 
according to pathologic stage, there were no significant 
difference with PIK3CA amplification in DFS (5-year DFS 
38.1% vs 57.3% in stage II [P=0.074]; 16.1% vs 28.8% in 
stage III [P=0.356], Supplementary Figure S2).
We next explored the role of adjuvant treatment 
according to PIK3CA amplification. We additionally 
analyzed survival outcome for two subgroups: one group 
without treatment (n=396) and another group with adjuvant 
chemotherapy and/or radiotherapy (n=138). In the adjuvant 
group, PIK3CA amplification showed an inferior DFS 
but it was statistically insignificant (median DFS 21.0 vs 
22.8 months, P=0.39, Supplementary Figure 3A). Among 
the patients without adjuvant treatment, the PIK3CA 
amplification group had a significantly shorter DFS 
compared with non-amplified group (median DFS 33.5 vs 
96.5 months, P=0.011, Supplementary Figure S3B).
PIK3CA mutations
Among the 526 patients, we examined PIK3CA 
exon 9 and 20 mutations using direct sequencing in 388 
cases with FFPE tissues available. PIK3CA mutations 
were detected in 6 (1.5%) of 388 cases; 5 cases in exon 
9 only, and 1 case in exon 20 only. The clinicopathologic 
characteristics of the 6 patients with PIK3CA mutations 
are listed in Table 3. PIK3CA exon 9 mutations were 
identified in 5 tumors of E545K (GAG to AAG), while 
exon 20 mutation was identified in H1047L (CAT to 
CTT) (Figure 3). No co-occurrence of exon 9 and exon 
20 mutations was identified. Of 6 PIK3CA mutants, the 
single case with exon 20 mutation satisfied the criteria of 
PIK3CA amplification with PIK3CA/CEN3 ratio of 2.5. 
The patient was diagnosed as stage IIB, upper ESCC 
with well-differentiated histology. He had experienced 
recurrence within 6 months after esophagectomy and died 
of disease. Though the statistical insignificance, all 6 cases 
were high T stage (5 with T3 and 1 with T4) and 4 out of 6 
cases (66.7%) were lymph node negative. Furthermore, all 
Figure 2: Survival analysis according to PIK3CA amplification. A. Median disease-free survival (DFS) was 33.4 months in 
the PIK3CA amplification group and 63.1 months in the no amplification group. B. Median overall survival (OS) was 52.1 months in the 
amplification group and 96.5 months in the no amplification group.
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tumors with PIK3CA mutations originated from the mid-
to-lower esophageal region. No prognostic difference in 
DFS (P=0.876) and OS (P=0.695) was detected according 
to the presence of PIK3CA mutation.
DISCUSSION
We conducted this study to examine the frequency 
and prognostic impact of PIK3CA amplification among 
curatively resected ESCCs. To our knowledge, this 
is the first study of PIK3CA amplification in a large 
cohort of East Asian ESCC patients. We found that 
PIK3CA amplification is a common genetic event and an 
independent poor prognostic factor in ESCC.
Though the known therapeutic options in EAC 
such as HER2 inhibitor, ESCC still lacks therapeutically 
relevant genetic alterations. In the era of personalized 
medicine, EAC and ESCC show different genetic 
aberrations for therapeutic strategies. A recent comparative 
genome study reported focal regions of DNA amplification 
or loss including SOX2, PIK3CA, CCND1, and FGFR1 
are more frequent in ESCC than EAC [9]. A study of DNA 
copy number profiles also revealed frequent alterations 
of the 3q22-26 regions containing PIK3CA in ESCC 
patients [10]. Therefore, PIK3CA may be a putative drive 
gene for ESCC with the available therapeutic agents and 
examining PIK3CA aberrations in a large cohort of ESCC 
is worthwhile.
Activation of the PI3K pathway, generally as a 
result of PIK3CA amplification, has been reported in 
upper aerodigestive tract cancers including 12% of 
lung squamous cell carcinoma (SCC) [23], 18.2% of 
nasopharyngeal carcinoma [24], 20% of oropharyngeal 
SCC [25], and 32.2% of HNSCC [16]. For esophageal 
carcinoma, one study demonstrated 26.7% of PIK3CA 
gene amplification in ESCC [18]. With FISH analysis, 
we found an overall 10.5% frequency of PIK3CA 
amplification.
Regarding the prognostic significance of PIK3CA 
amplification, previous reports yielded controversial 
Table 3: Clinicopathologic characteristics of 6 patients with PIK3CA mutation
No. Mutation Domain Age/Sex Stage Histology Recur Death PIK3CA 
amplification
1 E545K Helical Male/56 IIA (T3N0) Well No No No
2 E545K Helical Male/54 IIB (T3N0) Moderate Yes Yes No
3 E545K Helical Male/65 IIIA (T3N1) Well No No No
4 E545K Helical Male/61 IIIA (T3N1) Moderate Yes Yes No
5 E545K Helical Male/59 IIIA (T4N0) Moderate No No No
6 H1047L Kinase Male/66 IIB (T3N0) Well Yes Yes Amplified
Table 2: Survival outcome in multivariate analysis
Variable Category DFS OS
Univariate 
P value
HR 95% CI P HR 95% CI P
Sex Female vs Male (ref) 0.32 0.80 0.48-1.33 0.39 0.82 0.46-1.41 0.47
Location Lower vs upper/middle 0.07 1.63 1.13-2.35 0.008 1.53 1.04-2.24 0.03
Pathologic stage* II/III vs I (ref) <0.001 2.32 1.80-2.99 <0.001 2.79 2.14-3.66 <0.001
Histology
Poor vs well/moderate 
(ref) 0.06 1.34 0.99-1.80 0.06 1.32 0.96-1.80 0.08
Adjuvant treatment Yes vs no (ref) 0.05 1.22 0.93-1.61 0.16 1.05 0.79-1.39 0.75
PIK3CA 
amplification
Amplification vs no 
amplification (ref)
0.01 1.53 1.10-2.17 0.02 1.21 0.83-1.77 0.30
Abbreviations: DFS, disease-free survival; OS, overall survival; ref, reference; amp, amplification;
*Clinical stage at the time of initial diagnosis was determined according to the American Joint Committee on Cancer 
(seventh edition) guidelines
Oncotarget30697www.impactjournals.com/oncotarget
results. In nasopharyngeal carcinoma, PIK3CA 
amplification was strongly associated with distant 
metastasis, lymph node involvement, advanced tumor 
stage, and ultimately with reduced overall survival [24]. 
For non-lymph node metastatic HNSCC, patients with 
PIK3CA amplification showed earlier recurrence than 
those without (10% vs 31% disease free at 2 years) 
[16]. Angulo et al reported that PIK3CA amplification 
was significantly more frequent in lung SCC compared 
with adenocarcinoma (42% vs 3%, P<0.001), however, 
no association was found with other clinicopathologic 
characteristics [15]. Clinicopathologic heterogeneity 
including primary tumor, pathologic stage, and adjuvant 
treatment, may contribute to the controversial results. 
Furthermore, conclusions based on small sample sizes 
may lead to inconsistent results. In our study, by carefully 
assessing a large cohort of ESCC cases, we were able 
to clarify the prognostic value of PIK3CA amplification 
in a homogenous ESCC patients. Therefore, PIK3CA 
amplification was significantly associated with shorter 
DFS regardless of sex, histologic grade, and adjuvant 
therapy, implying a potential role as an independent 
negative prognostic factor in curatively resected ESCC.
To investigate PIK3CA gene copy number gain, 
most commonly used methods are real-time quantitative 
polymerase chain reaction (PCR) and in situ hybridization 
[15, 16, 18, 24, 26, 27]. With PCR studies, it is difficult to 
compare results among studies because of different cut-
off value; some studies used copy number more than 4 
[16, 28] whereas other group considered 2 or 3 copies as 
amplification [18, 23]. In contrast, relatively consistent 
criteria are used for FISH studies. The majority of studies 
defined PIK3CA amplification as PIK3CA/CEP3 ≥ 2 [25-
27] and another group defined it as copy number more than 
5 [15]. In our large cohort study, we used a combination of 
these criteria and demonstrated a significant difference in 
prognostic value. In our study, 26.7% of cases with copy 
number ≥5 might not have been considered amplified if 
Figure 3: Representative sequence chromatogram of A. E545K (G1634A) and B. H1047L (A3140T) mutation.
Oncotarget30698www.impactjournals.com/oncotarget
only the ratio criterion of ratio ≥ 2.0 was used. FISH is 
also more powerful than PCR by allowing visualization of 
individual cancer cells in a routine clinical environment. 
Identification PIK3CA amplification by FISH analysis 
may contribute to easy subgroups selection. Our criteria 
should be further validated in other solid tumors and in 
clinical trials with PI3K inhibitors.
Hotspot mutations of PIK3CA in exon 9 and exon 20 
have been shown to increase lipid kinase activity, leading 
to downstream activation [29]. The frequency of PIK3CA 
mutation has been variously reported as 2.2 to 21% of 
ESCC cases, with controversial prognostic value [19-22]. 
Mori et al identified a frequency of 2.2% using PCR-based 
direct sequencing [30] and Hou et al reported a frequency 
of 12.5 % with mutant-enriched liquid chip technology 
[19]. More recently, Shingaki et al identified PIK3CA 
mutations in 21% of cases by employing a pyrosequencing 
approach [22]. Here, we report PIK3CA mutations in 
1.6% of ESCCs using standard, bidirectional Sanger 
sequencing. Different sequencing methodologies may 
have an important influence on the reported frequencies. 
The limited sensitivity of Sanger sequencing may result 
in an apparent the low frequency and further studies to 
compare these multiple methods are warranted.
Elevated PI3K signaling correlates with PIK3CA 
mutation and/or amplification. In addition it is associated 
with increased activity of PI3K effector protein kinase B 
(PKB) [26] and pAkt [31], suggesting that these may be 
susceptible to PI3K inhibitors. In lung cancer cell lines, 
37% of squamous cell harbored PIK3CA amplification and 
they were sensitive to PI3K inhibitor GDC-0941 with less 
than 1μmol/L of IC50 [31]. In a preclinical platform from 
Cancer Cell Line Encyclopedia, PIK3CA-amplified tumors 
were sensitive to BYL719, a PI3K α-selective inhibitor 
[32]. Cell lines with PIK3CA amplification was positively 
associated with BYL719 sensitivity (P=0.0037) and 
tumor-bearing mice with PIK3CA amplification responded 
to BYL719, leading to a response rate of -18% (lung 
cancer) and -80% (gastric cancer). Despite the preliminary 
data, recent phase I trials have explored the potential 
predictive role of the PIK3CA gene. Pan-PI3K (BKM120 
and GDC-0941) and α-selective inhibitors (BYL719 
and GDC-0032) demonstrated responses and prolonged 
stable disease in patients with PIK3CA mutation [33-36]. 
In addition to PIK3CA mutation, PIK3CA amplification 
was positively associated with sensitivity to BYL719 in 
PIK3CA wild type cell lines [32]. In a phase I trial of 
GDC-0941, a heavily treated ovarian cancer patient with 
PIK3CA amplification achieved disease stabilization for 
4 months with significant pharmacodynamic changes 
[37]. To date, clinical trials with PI3K inhibitors have 
been reported in un-selected patients, and current trials 
with PI3K inhibitors are for patients with PIK3CA gene 
alterations are ongoing (ClinicalTrials.gov number 
NCT01928459 and NCT01608022). In addition, as shown 
in our study, frequency of PIK3CA amplification increases 
from 14.3% (stage I) to 50% (stage III) indicating more 
advanced patients may have benefit from PI3K inhibitors. 
Our results require further validation with PI3K inhibitors 
in clinical trials.
The main limitations of our study include its 
retrospective nature and patient selection. Therefore, our 
findings should be validated in an independent cohort and 
response data to PIK3CA-targeted therapies in the future 
clinical trials.
In conclusion, in our large cohort study, we 
demonstrated that PIK3CA amplification is an independent 
poor prognostic factor in resected ESCC. Our findings also 
provide strong implication that PIK3CA amplification and 
mutation is a promising therapeutic target in ESCC.
MATERIALS AND METHODS
Patients and tissue samples
A total of 534 patients with ESCC who underwent 
radical esophagectomy at Severance Hospital and 
Samsung Medical Center, Seoul, Korea between 2002 
and 2010 were enrolled in this study. The criteria used for 
patient selection included (1) surgically resected SCC of 
the thoracic esophagus (R0 resection), (2) availability of 
primary tumor tissue, (3) no distant metastasis, and (4) 
no preoperative treatment. Tumor samples were available 
for 664 patients, of which we excluded 107 cases (16.1%) 
who received neoadjuvant treatment. Twenty-three 
patients (3.5%) were excluded because of incomplete 
survival follow-up. All diagnosis were reviewed by 
two experienced pathologists (Y.L.C. and H.K.) and 
confirmed by hematoxylin and eosin staining. Paraffin-
embedded tumor specimens were used to construct a 
tissue microarray with three representative cores of 2-mm-
diameter.
Clinicopathologic characteristics and survival 
outcome was collected by reviewing the medical records. 
Staging was determined using the 7th edition of the 
American Joint Committee on Cancer guideline of tumor, 
node, and metastasis (TNM) classification. Smoking status 
of never-smoker, former smoker, and current smoker 
were defined as in previous studies (23). The study was 
approved by the institutional review board of Severance 
Hospital and Samsung Medical Center.
PIK3CA fluorescence in situ hybridization
To assess the presence of PIK3CA amplification, 
we performed fluorescence in situ hybridization (FISH) 
on tissue microarrays. PIK3CA (Spectrum Green) and 
CEP3 (Spectrum Orange) FISH was performed as per 
manufacturer’s recommendation. (Abbott Molecular, 
Abbott Park, IL, USA). Evaluation was performed 
independently by two experienced pathologists (Y.L.C. 
and H.K.K) blinded to clinical information, and at least 
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100 nuclei per case were evaluated. Based on the previous 
studies(24-27), PIK3CA amplification was defined as 
fulfillment of one of the following criteria: (1) PIK3CA/
CEP3 ratio ≥ 2.0 and (2) average number of PIK3CA 
signals per nucleus ≥ 5.0
Mutation analysis
Genomic DNA was extracted from 388 formalin-
fixed paraffin-embedded (FFPE) tissue specimens 
using a QIAamp DNA Micro kit (Qiagen, Valencia, 
CA, USA) according to the manufacturer’s instruction. 
The extracted DNA was used in a PCR amplification 
reaction with primers were designed to amplify the 
following regions at codon E542, E545 and H1047; exon 
9; 5’- AGAGACAATGAATTAAGGGAAAATGAC-3’; 
5’- TTTAGCACTTACCTGTGACTCCA-3’, exon 
20; 5’-TATTCGACAGCATGCCAATC-3’; 5’- 
TGTGTGGAAGATCCAATCCA-3’,.
PCR was carried out with the following conditions: 
initial denaturation at 95°C for 10 min, followed by 45 
cycles of 95°C for 30 s, 54°C for 60 s, 72°C for 45 s 
and a final polymerization step of 72°C for 5 min in a 
GeneAmp PCR system 2720 (Life technologies, CA, 
USA). The amplified DNA product was visualized by gel 
electrophoresis and PCR products were sequenced using 
the Big Dye terminator sequencing kit (Life technologies, 
CA, USA) according to the manufactures’ instruction. 
Sequence reactions were the subjected to electrophoresis 
on an Applied Biosystems 3130XL DNA Analyzer (Life 
Technologies, CA, USA).
Statistical analysis
We analyzed the association between PIK3CA 
amplification status and clinical significance using 
the χ2 test or Fisher’s exact test. We also assessed the 
prognostic value of PIK3CA amplification on survival 
outcome using Kaplan-Meier curves with a log-rank test. 
Disease free survival (DFS) was defined from the time of 
surgery to initial relapse or death. Overall survival (OS) 
was measured from the time of surgery to death or the 
last follow-up date, and 95% confidence intervals (CIs) 
were evaluated by survival analysis using the Kaplan-
Meier method. Statistical significance was defined as P < 
0.05 for all analyses. Multivariate analysis was done using 
Cox regression analysis for following variables: gender, 
location, pathologic stage, histology, adjuvant treatment, 
and PIK3CA amplification status. All statistical analysis 
was performed using SPSS version 18.0 (SPSS, Chicago, 
IL, USA).
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